Liver transduction with a simian virus 40 vector encoding insulin-like growth factor I reduces hepatic damage and the development of liver cirrhosis

Maria Vera Ugalde, L. Sobrevals, M. Zaratiegui, L. Martinez, B. Palencia, C. M. Rodríguez, J. Prieto, P. Fortes

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Liver transplantation is the only treatment for advanced liver cirrhosis. Therapies halting the progression of the disease are urgently needed. Administration of recombinant insulin-like growth factor-I (rIGF-I) induces hepatoprotective effects in experimental cirrhosis. Therefore, we analyzed the efficacy of a recombinant simian virus 40 vector (rSV40) encoding IGF-I (rSVIGF-I) to prevent cirrhosis progression. First, transgene expression was evaluated in mice injected with rSV40 encoding luciferase, which showed long-term hepatic expression of the transgene. Interestingly, luciferase expression increased significantly in CCl4-damaged livers and upon IGF-I administration, thus liver injury and IGF-I expression from rSVIGF-I should favor transgene expression. rSVIGF-I therapeutic efficacy was studied in rats where liver cirrhosis was induced by CCl4 inhalation during 36 weeks. At the end of the study, the hepatic levels of IGF-I and IGF-binding protein 3 were higher in rSVIGF-I-treated rats than in control cirrhotic animals. Cirrhotic rats treated with rSVIGF-I had reduced serum bilirubin, transaminases and liver fibrosis scores and increased hepatic expression of hepatocyte growth factor and STAT3α as compared to cirrhotic animals. Furthermore, cirrhotic animals showed testis atrophy and altered spermatogenesis, whereas testicular size and histology were normal in cirrhotic rats that received rSVIGF-I. Therefore, rSV40-mediated sustained expression of IGF-I in the liver slowed cirrhosis progression.

Original languageEnglish (US)
Pages (from-to)203-210
Number of pages8
JournalGene Therapy
Volume14
Issue number3
DOIs
StatePublished - Feb 2007
Externally publishedYes

Fingerprint

Simian virus 40
Insulin-Like Growth Factor I
Liver Cirrhosis
Liver
Transgenes
Luciferases
Fibrosis
Insulin-Like Growth Factor Binding Protein 3
Hepatocyte Growth Factor
Spermatogenesis
Transaminases
Bilirubin
Liver Transplantation
Inhalation
Atrophy
Disease Progression
Testis
Histology
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Vera Ugalde, M., Sobrevals, L., Zaratiegui, M., Martinez, L., Palencia, B., Rodríguez, C. M., ... Fortes, P. (2007). Liver transduction with a simian virus 40 vector encoding insulin-like growth factor I reduces hepatic damage and the development of liver cirrhosis. Gene Therapy, 14(3), 203-210. https://doi.org/10.1038/sj.gt.3302858

Liver transduction with a simian virus 40 vector encoding insulin-like growth factor I reduces hepatic damage and the development of liver cirrhosis. / Vera Ugalde, Maria; Sobrevals, L.; Zaratiegui, M.; Martinez, L.; Palencia, B.; Rodríguez, C. M.; Prieto, J.; Fortes, P.

In: Gene Therapy, Vol. 14, No. 3, 02.2007, p. 203-210.

Research output: Contribution to journalArticle

Vera Ugalde, M, Sobrevals, L, Zaratiegui, M, Martinez, L, Palencia, B, Rodríguez, CM, Prieto, J & Fortes, P 2007, 'Liver transduction with a simian virus 40 vector encoding insulin-like growth factor I reduces hepatic damage and the development of liver cirrhosis', Gene Therapy, vol. 14, no. 3, pp. 203-210. https://doi.org/10.1038/sj.gt.3302858
Vera Ugalde, Maria ; Sobrevals, L. ; Zaratiegui, M. ; Martinez, L. ; Palencia, B. ; Rodríguez, C. M. ; Prieto, J. ; Fortes, P. / Liver transduction with a simian virus 40 vector encoding insulin-like growth factor I reduces hepatic damage and the development of liver cirrhosis. In: Gene Therapy. 2007 ; Vol. 14, No. 3. pp. 203-210.
@article{300224d8091a4b0ab639bbeb830f6ec8,
title = "Liver transduction with a simian virus 40 vector encoding insulin-like growth factor I reduces hepatic damage and the development of liver cirrhosis",
abstract = "Liver transplantation is the only treatment for advanced liver cirrhosis. Therapies halting the progression of the disease are urgently needed. Administration of recombinant insulin-like growth factor-I (rIGF-I) induces hepatoprotective effects in experimental cirrhosis. Therefore, we analyzed the efficacy of a recombinant simian virus 40 vector (rSV40) encoding IGF-I (rSVIGF-I) to prevent cirrhosis progression. First, transgene expression was evaluated in mice injected with rSV40 encoding luciferase, which showed long-term hepatic expression of the transgene. Interestingly, luciferase expression increased significantly in CCl4-damaged livers and upon IGF-I administration, thus liver injury and IGF-I expression from rSVIGF-I should favor transgene expression. rSVIGF-I therapeutic efficacy was studied in rats where liver cirrhosis was induced by CCl4 inhalation during 36 weeks. At the end of the study, the hepatic levels of IGF-I and IGF-binding protein 3 were higher in rSVIGF-I-treated rats than in control cirrhotic animals. Cirrhotic rats treated with rSVIGF-I had reduced serum bilirubin, transaminases and liver fibrosis scores and increased hepatic expression of hepatocyte growth factor and STAT3α as compared to cirrhotic animals. Furthermore, cirrhotic animals showed testis atrophy and altered spermatogenesis, whereas testicular size and histology were normal in cirrhotic rats that received rSVIGF-I. Therefore, rSV40-mediated sustained expression of IGF-I in the liver slowed cirrhosis progression.",
author = "{Vera Ugalde}, Maria and L. Sobrevals and M. Zaratiegui and L. Martinez and B. Palencia and Rodr{\'i}guez, {C. M.} and J. Prieto and P. Fortes",
year = "2007",
month = "2",
doi = "10.1038/sj.gt.3302858",
language = "English (US)",
volume = "14",
pages = "203--210",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Liver transduction with a simian virus 40 vector encoding insulin-like growth factor I reduces hepatic damage and the development of liver cirrhosis

AU - Vera Ugalde, Maria

AU - Sobrevals, L.

AU - Zaratiegui, M.

AU - Martinez, L.

AU - Palencia, B.

AU - Rodríguez, C. M.

AU - Prieto, J.

AU - Fortes, P.

PY - 2007/2

Y1 - 2007/2

N2 - Liver transplantation is the only treatment for advanced liver cirrhosis. Therapies halting the progression of the disease are urgently needed. Administration of recombinant insulin-like growth factor-I (rIGF-I) induces hepatoprotective effects in experimental cirrhosis. Therefore, we analyzed the efficacy of a recombinant simian virus 40 vector (rSV40) encoding IGF-I (rSVIGF-I) to prevent cirrhosis progression. First, transgene expression was evaluated in mice injected with rSV40 encoding luciferase, which showed long-term hepatic expression of the transgene. Interestingly, luciferase expression increased significantly in CCl4-damaged livers and upon IGF-I administration, thus liver injury and IGF-I expression from rSVIGF-I should favor transgene expression. rSVIGF-I therapeutic efficacy was studied in rats where liver cirrhosis was induced by CCl4 inhalation during 36 weeks. At the end of the study, the hepatic levels of IGF-I and IGF-binding protein 3 were higher in rSVIGF-I-treated rats than in control cirrhotic animals. Cirrhotic rats treated with rSVIGF-I had reduced serum bilirubin, transaminases and liver fibrosis scores and increased hepatic expression of hepatocyte growth factor and STAT3α as compared to cirrhotic animals. Furthermore, cirrhotic animals showed testis atrophy and altered spermatogenesis, whereas testicular size and histology were normal in cirrhotic rats that received rSVIGF-I. Therefore, rSV40-mediated sustained expression of IGF-I in the liver slowed cirrhosis progression.

AB - Liver transplantation is the only treatment for advanced liver cirrhosis. Therapies halting the progression of the disease are urgently needed. Administration of recombinant insulin-like growth factor-I (rIGF-I) induces hepatoprotective effects in experimental cirrhosis. Therefore, we analyzed the efficacy of a recombinant simian virus 40 vector (rSV40) encoding IGF-I (rSVIGF-I) to prevent cirrhosis progression. First, transgene expression was evaluated in mice injected with rSV40 encoding luciferase, which showed long-term hepatic expression of the transgene. Interestingly, luciferase expression increased significantly in CCl4-damaged livers and upon IGF-I administration, thus liver injury and IGF-I expression from rSVIGF-I should favor transgene expression. rSVIGF-I therapeutic efficacy was studied in rats where liver cirrhosis was induced by CCl4 inhalation during 36 weeks. At the end of the study, the hepatic levels of IGF-I and IGF-binding protein 3 were higher in rSVIGF-I-treated rats than in control cirrhotic animals. Cirrhotic rats treated with rSVIGF-I had reduced serum bilirubin, transaminases and liver fibrosis scores and increased hepatic expression of hepatocyte growth factor and STAT3α as compared to cirrhotic animals. Furthermore, cirrhotic animals showed testis atrophy and altered spermatogenesis, whereas testicular size and histology were normal in cirrhotic rats that received rSVIGF-I. Therefore, rSV40-mediated sustained expression of IGF-I in the liver slowed cirrhosis progression.

UR - http://www.scopus.com/inward/record.url?scp=33846556910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846556910&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302858

DO - 10.1038/sj.gt.3302858

M3 - Article

C2 - 17024107

AN - SCOPUS:33846556910

VL - 14

SP - 203

EP - 210

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 3

ER -